Cellectis (CLLS) Capital Leases (2021 - 2022)
Cellectis (CLLS) recorded quarterly Capital Leases of $89000.0 in Q1 2022, down 99.49% quarter-over-quarter from $17.5 million in Q4 2021.
Cellectis (CLLS) Capital Leases (2021 - 2022) Analysis & Trends
Cellectis' Capital Leases history runs 2 years deep, the most recent figure standing at $89000.0 for Q1 2022.
- In Q1 2022, Capital Leases changed N/A year-over-year to $89000.0; the TTM figure through Mar 2022 stood at $89000.0 (changed N/A YoY), while the FY2021 annual figure was $17.5 million, changed N/A from the prior year.
- Capital Leases was $89000.0 for Q1 2022 at Cellectis, down from $17.5 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $17.5 million in Q4 2021 to a low of $89000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 89,000.00 |
| Dec 31, 2021 | 17.51 Mn |